This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Medtronic's (MDT) Emprint Ablation System Study Data Positive
by Zacks Equity Research
Medtronic's (MDT) Emprint Ablation Catheter Kit received Breakthrough Device Designation status from the FDA in April 2021 and is currently in development.
Here's Why You Should Invest In Henry Schein (HSIC) Now
by Zacks Equity Research
Investors are optimistic about Henry Schein (HSIC) owing to strong segmental performance and strategic buyouts and collaborations.
Insulet (PODD) Gains on Omnipod Sales Amid Cost Pressure
by Zacks Equity Research
Insulet (PODD) is gradually improving with respect to seamless supply chain and manufacturing operations.
Omnicell (OMCL) Opens New Software Development Center in India
by Zacks Equity Research
Omnicell's (OMCL) new software development center in Bangalore, India, is expected to bolster the company's cloud-based solutions portfolio.
Abbott (ABT) Hits a New 52-Week High: What's Driving It?
by Zacks Equity Research
Investors are optimistic about Abbott (ABT) on solid second-quarter performance and continued adoption of FreeStyle Libre worldwide.
LHC Group (LHCG) Closes Heart of Hospice Buyout, Expands Presence
by Zacks Equity Research
LHC Group (LHCG) expands its hospice presence in five states with the completion of Heart of Hospice buyout.
Here's Why You Should Retain AmerisourceBergen (ABC) Stock Now
by Zacks Equity Research
AmerisourceBergen (ABC) continues to gain traction from the robust pharmaceutical segment.
Thermo Fisher (TMO)-AstraZeneca to Co-Develop NGS-Based CDx
by Zacks Equity Research
Thermo Fisher's (TMO) new collaboration with AstraZeneca is intended to speed up development and introduction of targeted precision medicine therapies for patients.
Masimo (MASI) Ties Up to Educate on Prescription Opioid Overuse
by Zacks Equity Research
Masimo (MASI) partners with Penington Institute to increase awareness on overdose from prescription opioids.
QIAGEN (QGEN) to Join DAX Riding on Molecular Diagnostics Feat
by Zacks Equity Research
QIAGEN (QGEN) is experiencing significant improvements in non-COVID areas of its molecular diagnostics portfolio.
Hill-Rom (HRC) Agrees to Get Acquired by Baxter, Shares Jump
by Zacks Equity Research
The transaction is expected to close by early 2022 subject to the approval of Hill-Rom (HRC) shareholders and the fulfillment of customary closing conditions.
Abbott (ABT) Expands Vascular Portfolio With New Acquisition
by Zacks Equity Research
Abbott's (ABT) acquisition of Walk Vascular's Peripheral Thrombectomy Systems will be included into the former's existing endovascular product portfolio.
Boston Scientific (BSX) New Buyout to Aid Kidney Stone Line
by Zacks Equity Research
Boston Scientific (BSX) shares a 20-year long relationship with Lumenis and already offers the Lumenis urology laser portfolio in the United States and Japan through a distribution arrangement.
Here's Why You Should Retain Stryker (SYK) Stock Right Now
by Zacks Equity Research
Stryker (SYK) continues to benefit from strength in the robotic-arm assisted surgery platform, Mako, and broad product portfolio. However, pricing pressure raises a concern.
Smith+Nephew (SNN) Releases New Features for Hip Arthroplasty
by Zacks Equity Research
Smith+Nephew (SNN) introduced the RI.HIP NAVIGATION software on the CORI Surgical System and announced the commercial availability of RI.INSIGHTS at the AAOS 2021 Annual Meeting.
Orthofix (OFIX) Fitbone Used in 1st US Pediatric Patient Implant
by Zacks Equity Research
Orthofix's (OFIX) Fitbone system is the only intramedullary limb lengthening solution to get FDA clearance for pediatric and adult use.
Abbott's (ABT) Heart Failure Device Study Outcome Favorable (Revised)
by Zacks Equity Research
Based on the favorable outcome, Abbott (ABT) files a Premarket Approval (PMA) supplement with the FDA for consideration of an expanded indication for the CardioMEMS device.
Here's Why You Should Retain Haemonetics (HAE) Stock for Now
by Zacks Equity Research
Strong recovery across businesses and strength in plasma franchise benefited Haemonetics (HAE) during the first quarter of fiscal 2022.
Zimmer Biomet's (ZBH) Data Favors mymobility with Apple Watch
by Zacks Equity Research
Zimmer Biomet (ZBH) presented four data presentations backing the mymobility with Apple Watch platform at the AAOS 2021 Annual Meeting.
NextGen's (NXGN) Solutions to Boost Care for Homeless Community
by Zacks Equity Research
NextGen's (NXXGN) solutions collaborate with Neighborhood Health to provide care to Nashville's homeless community through the latter's street medicine program.
Walgreens (WBA) to Stock LUCEMYRA Across US With New Pact
by Zacks Equity Research
Walgreens' (WBA) agreement with US WorldMeds finalized as recent report outlines a surge of 30% in drug overdose deaths in 2020.
Cardiovascular Systems (CSII) Introduces Diamondback in Canada
by Zacks Equity Research
The introduction of Cardiovascular Systems' (CSII) Diamondback 360 Coronary OAS in Canada will offer physicians an effective treatment option for patients with coronary artery diseases.
Here's Why You Should Retain McKesson (MCK) Stock Right Now
by Zacks Equity Research
McKesson (MCK) continues to benefit from its robust Distribution Solutions segment.
Masimo (MASI) Strengthens Global Footprint With New Launch
by Zacks Equity Research
Masimo's (MASI) western Europe launch of SafetyNet Alert not only expands its global presence but also aids in protecting patients taking opioids at home.
Abbott's (ABT) Amplatzer Amulet Occluder Trial Data Favorable
by Zacks Equity Research
Abbott's (ABT) Amulet IDE trial findings supported the recent FDA approval of Abbott's Amplatzer Amulet LAA Occluder to reduce the risk of stroke in patients with atrial fibrillation.